Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for Helicobacter pylori eradication?

References

• Suerbaum S, Michetti P. Helicobacter pylori infection. N. Engl. J. Med.347, 1175–1186 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol.42, 1–15 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Iwasaki E, Hibi T. Helicobacter pylori and gastric cancer. Gastric Cancer12, 79–87 (2009).
   PubMed Web of Science ®Google Scholar
• Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter15, 1–20 (2010).
   PubMed Web of Science ®Google Scholar
• Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet372, 392–397 (2008).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut56, 772–781 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol.5, 639–648 (2010).
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut59, 1143–1153 (2010).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current European concepts in the management of Helicobacter pylori infection – the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur. J. Gastroenterol. Hepatol.9, 1–2 (1997).
   PubMed Web of Science ®Google Scholar
• Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol.102, 1808–1825 (2007).
   PubMed Web of Science ®Google Scholar
• O’Morain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment. Pharmacol. Ther.17, 415–420 (2003).
   PubMedGoogle Scholar
• Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, Phase III trial. Lancet377, 905–913 (2011).
   PubMed Web of Science ®Google Scholar
• Masaoka T, Suzuki H, Kurabayashi K, Kamiya AG, Ishii H. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment. Pharmacol. Ther.20(Suppl. 1), 68–73 (2004).
   PubMedGoogle Scholar
• Kaneko F, Suzuki H, Hasegawa N et al. High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. Aliment. Pharmacol. Ther.20(Suppl. 1), 62–67 (2004).
   PubMedGoogle Scholar
• Nishizawa T, Suzuki H, Masaoka T, Iwasaki E, Hibi T. A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori. Digestion76, 215–220 (2007).
   PubMed Web of Science ®Google Scholar
• Hirata K, Suzuki H, Nishizawa T et al. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J. Gastroenterol. Hepatol.25(Suppl. 1), S75–S79 (2010).
   PubMedGoogle Scholar
• Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol.98, 562–567 (2003).
   PubMed Web of Science ®Google Scholar
• Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology123, 1763–1769 (2002).
   PubMed Web of Science ®Google Scholar
• Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment. Pharmacol. Ther.26, 343–357 (2007).
   PubMed Web of Science ®Google Scholar
• Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am. J.Gastroenterol.105, 65–73 (2010).
   PubMed Web of Science ®Google Scholar
• Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J. Clin. Pathol.41, 207–210 (1988).
   PubMed Web of Science ®Google Scholar
• Graham DY, Opekun AR, Belson G, El-Zimaity HM, Carlson MR. Novel bismuth–metronidazole–tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment. Pharmacol. Ther.21, 165–168 (2005).
   PubMedGoogle Scholar
• Domenico P, Reich J, Madonia W, Cunha BA. Resistance to bismuth among gram-negative bacteria is dependent upon iron and its uptake. J. Antimicrob. Chemother.38, 1031–1040 (1996).
   PubMed Web of Science ®Google Scholar
• Bland MV, Ismail S, Heinemann JA, Keenan JI. The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation. Antimicrob. Agents Chemother.48, 1983–1988 (2004).
   PubMed Web of Science ®Google Scholar
• Tsugawa H, Suzuki H, Satoh K et al. Two amino acids mutation of ferric uptake regulator determines Helicobacter pylori resistance to metronidazole. Antioxid. Redox Signal.14, 15–23 (2011).
   PubMedGoogle Scholar
• Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int. J. Antimicrob. Agents17, 39–44 (2001).
   PubMed Web of Science ®Google Scholar
• Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J. Gastroenterol.14, 7361–7370 (2008).
   PubMed Web of Science ®Google Scholar
• Hoshiya S, Watanabe K, Tokunaga K et al. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J. Gastroenterol.35, 10–14 (2000).
   PubMedGoogle Scholar
• Romano M, Cuomo A, Gravina AG et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut59, 1465–1470 (2010).
   PubMed Web of Science ®Google Scholar
• Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut56, 1353–1357 (2007).
   PubMed Web of Science ®Google Scholar
• Nishizawa T, Suzuki H, Tsugawa H et al. Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication. Antimicrob. Agents Chemother.55, 3012–3014 (2011).
   PubMedGoogle Scholar
• Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther.14, 603–609 (2000).
   PubMed Web of Science ®Google Scholar
• van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol.94, 1751–1759 (1999).
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C et al. Worldwide H. pylori antibiotic resistance: a systematic review. J. Gastrointestin. Liver Dis.19, 409–414 (2010).
   PubMed Web of Science ®Google Scholar
• Cheon JH, Kim N, Lee DH et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter11, 46–51 (2006).
   PubMed Web of Science ®Google Scholar
• Perri F, Festa V, Clemente R et al. Randomized study of two ‘rescue’ therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol.96, 58–62 (2001).
   PubMed Web of Science ®Google Scholar